Truist raised the firm’s price target on Teva (TEVA) to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: